Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Biological therapy, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing.

PURPOSE: This phase I trial is studying how well cellular adoptive immunotherapy works in treating a patient who has undergone a donor stem cell transplant for breast cancer that has spread to the lung.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Aldesleukin; Paclitaxel; Trastuzumab

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of stage IIB HER2/neu-expressing breast cancer 6½ years ago

• Received a T-cell-depleted allogeneic stem cell transplantation (SCT) from a 6/6 HLA-matched sibling donor for refractory metastatic breast cancer

• Developed pulmonary metastases during adjuvant chemotherapy following modified radical mastectomy

• Pulmonary metastases progressed after prior allogeneic SCT

• Responded in an objective and measurable manner to prior allogeneic lymphocyte infusion, post-transplantation chemotherapy, and trastuzumab (Herceptin®)

• Disease limited to the thoracic cavity

• Operable tumor with at least 1 cm of surgically accessible lesion

• Preoperative risk assessment indicating ≤ 5% risk of mortality and < 15% risk of significant morbidity for pulmonary metastasectomy

• Enrolled on protocol CC# 00-C-0119

• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Female

• Menopausal status not specified

• ECOG performance status 0-2

• Life expectancy > 6 months

• Negative pregnancy test

• Adequate pulmonary reserve

• Prior graft-versus-host disease (GVHD) ≤ grade 1

• No concurrent GVHD

• No active infection nonresponsive to antimicrobial therapy

• No active psychiatric disorder that would preclude study compliance

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• At least 4 weeks since prior systemic immunosuppressive therapy

• At least 2 weeks since prior cytotoxic therapy and immunotherapy (e.g. trastuzumab [Herceptin®])

• No concurrent immunosuppressive therapy